CC-5013 [lenalidomide; Revlimid] Alone or in Combination With Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.
- 19 Nov 2015 Planned primary completion date changed to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 31 Aug 2010 Planned end date (Jun 2006) added as reported by ClinicalTrials.gov.